Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F2 | P00734 | 3/20 | 0.47 |
| ▸ | P2RY2 | P41231 | 13/20 | 0.47 |
| ▸ | P2RY4 | P51582 | 9/20 | 0.47 |
| ▸ | P2RY6 | Q15077 | 7/20 | 0.45 |
| ▸ | POLA1 | P09884 | 1/20 | 0.44 |
| ▸ | DUT | P33316 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Biotin SCHEMBL381578 | 0.88 | DUT (0.52) | F2P2RY2P2RY4P2RY6POLA1 | |
| Uridine Triphosphate SCHEMBL166686 | 0.83 | P2RY2 (0.61) | P2RY2P2RY4P2RY6 | |
| SCHEMBL2808581 | 0.81 | F2 (0.51) | F2DUT | |
| SCHEMBL15794560 | 0.78 | HLCS (0.51) | F2 | |
| SCHEMBL14204816 | 0.77 | P2RY2 (0.54) | P2RY2P2RY4P2RY6 | |
| Biotin SCHEMBL4304275 | 0.77 | TDP1 (0.44) | F2P2RY2P2RY4P2RY6DUT | |
| SCHEMBL14204819 | 0.77 | P2RY6 (0.54) | P2RY2P2RY4P2RY6 | |
| Biotin SCHEMBL523980 | 0.76 | TDP1 (0.51) | F2DUT | |
| SCHEMBL21787064 | 0.74 | F2 (0.48) | F2POLA1 | |
| SCHEMBL21786921 | 0.74 | F2 (0.48) | F2POLA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170008940-A1 | Mucin Derived Polypeptides | MuciMed, Inc. | 2017-01-12 | — | — | US | disclosed |
| US-9119869-B2 | Mucin derived polypeptides | MUCIMED, INC, | 2015-09-01 | — | — | US | disclosed |
| WO-2014036377-A1 | METHODS OF PROMOTING CELL VIABILITY | METSELEX (US) | 2014-03-06 | — | — | WO | disclosed |
| US-20130345073-A1 | USE OF ALPHA-2-MACROGLOBULIN FOR DETERMINING OSTEONECROSIS DISEASE STATUS AND FOR SCREENING THERAPEUTIC AGENTS FOR PREVENTING OR TREATING OSTEONECROSIS | THE ROYAL INSTITUTION FOR THE ADVANCEMENT OF LEARNING / MCGILL UNIVERSITY (CA) | 2013-12-26 | — | — | US | disclosed |
| US-20120122870-A1 | Treatment Of Ischemia-Reperfusion Injury | MUSC FOUNDATION FOR RESEARCH DEVELOPMENT (US) | 2012-05-17 | — | — | US | disclosed |
| US-20120028911-A1 | Mucin Derived Polypeptides | MuciMed, Inc. (US) | 2012-02-02 | — | — | US | disclosed |
| US-20110190218-A1 | BAG-1 PEPTIDE THAT INHIBITS PROSTATE CANCER | KARLSRUHE INSTITUTE OF TECHNOLOGY (DE) | 2011-08-04 | — | — | US | disclosed |
| US-20110190399-A1 | CURCUMIN NANOPARTICLES AND METHODS OF PRODUCING THE SAME | Kar, Santosh Kumar (IN) | 2011-08-04 | — | — | US | disclosed |
| EP-2349237-A2 | CURCUMIN NANOPARTICLES AND METHODS OF PRODUCING THE SAME | Kar, Santosh Kumar (IN) | 2011-08-03 | — | — | EP | disclosed |
| WO-2010129954-A1 | TREATMENT OF ISCHEMIA-REPERFUSION INJURY | APOGEE BIOTECHNOLOGY CORPORATION (US) | 2010-11-11 | — | — | WO | disclosed |
| EP-2151452-A1 | Bag-1 peptide that inhibits prostate cancer | Karlsruher Institut für Technologie (DE) | 2010-02-10 | — | — | EP | disclosed |
| WO-2010012452-A1 | BAG-1 PEPTIDE THAT INHIBITS PROSTATE CANCER | KARLSRUHE INSTITUTE OF TECHNOLOGY (DE) | 2010-02-04 | — | — | WO | disclosed |
| WO-2010013224-A2 | CURCUMIN NANOPARTICLES AND METHODS OF PRODUCING THE SAME | KAR SANTOSH KUMAR (IN) | 2010-02-04 | — | — | WO | disclosed |
| EP-0983069-B1 | USE OF TAUROLIDINE FOR the manufacture of a medicament for the TREATMENT OF LEUKEMIAS | OKLAHOMA MED RES FOUND (US) | 2004-08-04 | — | — | EP | disclosed |
| US-6303596-B1 | ADMINISTERING EFFECTIVE AMOUNT OF TAUROLIDINE TO RENDER LEUKEMIA-CAUSING CELLS APOPTOTIC | OKLAHOMA MEDICAL RESEARCH FOUNDATION | 2001-10-16 | — | — | US | disclosed |
| EP-0983069-A1 | USE OF TAUROLIDINE FOR TREATMENT OF LEUKEMIAS | Oklahoma Medical Research Foundation (US) | 2000-03-08 | — | — | EP | disclosed |
| WO-1998052572-A1 | USE OF TAUROLIDINE FOR TREATMENT OF LEUKEMIAS | OKLAHOMA MEDICAL RESEARCH FOUNDATION (US) | 1998-11-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120122870-A1 | Treatment Of Ischemia-Reperfusion Injury | SPHK1, SPHK2, S1PR2 | F2 662/4885P2RY2 1585/4885P2RY4 2124/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.